Dataset from A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.

This study will be conducted to characterize pharmacokinetics, pharmacodynamics, safety, and
tolerability of anifrolumab given via the subcutaneous (SC) route of administration in adult
Systemic Lupus Erythematosus (SLE) subjects with a type I Interferon (IFN) test high result
and active skin manifestations while receiving Standard of Care (SOC) treatment. In addition,
the efficacy of anifrolumab on SLE skin manifestations will be characterized.